Additional file 1 of Tumor necrosis factor-inducible gene 6 protein and its derived peptide ameliorate liver fibrosis by repressing CD44 activation in mice with alcohol-related liver disease

Additional file 1: Supplementary Figure 1. Pharmacokinetic properties of TSG-6 in mice with acute ALD. Supplementary Figure 2. Mice have liver injury with fibrosis at 9 weeks of Lieber–DeCarli alcohol liquid diet. Supplementary Figure 3. Vehicle treatment rarely impacts pathophysiological response of the liver to the diet feeding. Supplementary Figure 4. Liver fibrosis is induced by chronic consumption of EtOH in regardless of vehicle injection. Supplementary Figure 5. Localization of nuclear CD44ICD and α-SMA expression in TSG-6-treated human pHSCs. Supplementary Figure 6. Analysis of MMP14 expression in liver cells and ALD mice. Supplementary Figure 7. Design of peptides mimicking TSG-6 and inhibitory action of the peptide # 4 on HSC activation. Supplementary Figure 8. Localization of nuclear CD44ICD and α-SMA expression in YJ-given human pHSCs. Supplementary Figure 9. TSG-6 rarely impacts CD44ICD production in MMP14-suppressed human pHSCs. Supplementary Figure 10. Peptide YJ downregulated profibrotic genes in mice chronically fed EtOH. Supplementary Table 1. Primer list of qRT-PCR.